Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Mouse anti-Human IgD Antibody

FACS, IHC (fro) Monoclonal IA6-2 IgG2a kappa unconjugated
Catalog No. ABIN2749203
  • Target See all IgD products
    IgD
    Reactivity
    • 35
    • 11
    • 4
    Human
    Host
    • 22
    • 11
    • 7
    • 5
    • 5
    Mouse
    Clonality
    • 35
    • 14
    Monoclonal
    Application
    • 29
    • 20
    • 13
    • 11
    • 9
    • 9
    • 8
    • 5
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Specificity
    The mouse monoclonal antibody IA6-2 recognizes human immunoglobulin D.
    Cross-Reactivity (Details)
    Human
    Purification
    Purified by protein-A affinity chromatography.
    Purity
    > 95 % (by SDS-PAGE)
    Immunogen
    Human IgD
    Clone
    IA6-2
    Isotype
    IgG2a kappa
  • Application Notes
    Flow cytometry: Recommended dilution: 2-4 μg/mL.
    Restrictions
    For Research Use only
  • Concentration
    1 mg/mL
    Buffer
    Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C
    Storage Comment
    Store at 2-8°C. Do not freeze.
  • Degauque, Elong Ngono, Ngono, Akl, Lepetit, Crochette, Giral, Lepourry, Pallier, Castagnet, Dugast, Guillot-Gueguen, Jacq-Foucher, Saulquin, Cesbron, Laplaud, Nicot, Brouard, Soulillou: "Characterization of antigen-specific B cells using nominal antigen-coated flow-beads." in: PLoS ONE, Vol. 8, Issue 12, pp. e84273, (2014) (PubMed).

    Bunch, McGregor, Khandoobhai, Aybar, Burkart, Hu, Hogan, Poulton, Berg, Falk, Nachman: "Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab." in: Clinical journal of the American Society of Nephrology : CJASN, Vol. 8, Issue 3, pp. 382-91, (2013) (PubMed).

    Di Sabatino, Carsetti, Rosado, Ciccocioppo, Cazzola, Morera, Tinozzi, Tinozzi, Corazza: "Immunoglobulin M memory B cell decrease in inflammatory bowel disease." in: European review for medical and pharmacological sciences, Vol. 8, Issue 5, pp. 199-203, (2005) (PubMed).

    Pugh-Bernard, Silverman, Cappione, Villano, Ryan, Insel, Sanz: "Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance." in: The Journal of clinical investigation, Vol. 108, Issue 7, pp. 1061-70, (2001) (PubMed).

    Ferrari, Giliani, Insalaco, Al-Ghonaium, Soresina, Loubser, Avanzini, Marconi, Badolato, Ugazio, Levy, Catalan, Durandy, Tbakhi, Notarangelo, Plebani: "Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, Issue 22, pp. 12614-9, (2001) (PubMed).

    Baier, Baier-Bitterlich, Looney, Altman: "Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro." in: Journal of virology, Vol. 69, Issue 4, pp. 2357-65, (1995) (PubMed).

  • Target
    IgD
    Abstract
    IgD Products
    Target Type
    Antibody
    Background
    Immunoglobulin D (IgD) is expressed on the surface of naive mature B cells, thus later than IgM, and is coexpressed with it then. Triggered by antigen binding, it signals through the CD79 complex to activate the B cells. Expression of IgD is lost after the isotype switch. Soluble IgD is present in very small amounts in the serum. IgD can bind to basophils and mast cells to activate them in an IgE-independent way to participate in respiratory immune defense.,Immunoglobulin D
You are here:
Support